Establishment Labs (NASDAQ:ESTA) Sets New 52-Week High – Should You Buy?

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $83.78 and last traded at $83.1170, with a volume of 293524 shares. The stock had previously closed at $79.46.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ESTA. Mizuho lifted their price target on shares of Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. TD Cowen reiterated a “buy” rating on shares of Establishment Labs in a research note on Monday. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research note on Wednesday, May 6th. BTIG Research lifted their price target on shares of Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Friday, March 27th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $87.14.

Establishment Labs Price Performance

The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The stock’s 50 day simple moving average is $68.81 and its two-hundred day simple moving average is $69.17. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -55.13 and a beta of 1.11.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The business had revenue of $59.88 million for the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm’s quarterly revenue was up 44.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.70) EPS. On average, analysts forecast that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Insider Activity

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the transaction, the director directly owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 330,000 shares of company stock worth $22,854,538 over the last three months. 9.99% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. NewEdge Advisors LLC lifted its holdings in shares of Establishment Labs by 14.8% during the first quarter. NewEdge Advisors LLC now owns 10,284 shares of the company’s stock valued at $584,000 after acquiring an additional 1,327 shares during the period. Bank of America Corp DE lifted its holdings in shares of Establishment Labs by 56.7% during the first quarter. Bank of America Corp DE now owns 416,840 shares of the company’s stock valued at $23,668,000 after acquiring an additional 150,797 shares during the period. ADAR1 Capital Management LLC lifted its holdings in shares of Establishment Labs by 24.5% during the first quarter. ADAR1 Capital Management LLC now owns 213,473 shares of the company’s stock valued at $12,121,000 after acquiring an additional 42,051 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Establishment Labs by 42.3% during the first quarter. California State Teachers Retirement System now owns 22,120 shares of the company’s stock valued at $1,256,000 after acquiring an additional 6,579 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Establishment Labs during the first quarter valued at $318,000. 72.91% of the stock is owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.